Oramed PharmaceuticalsORMP
ORMP
About: Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Employees: 13
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
550% more call options, than puts
Call options by funds: $26K | Put options by funds: $4K
0.01% more ownership
Funds ownership: 19.02% [Q4 2024] → 19.03% (+0.01%) [Q1 2025]
7% less funds holding
Funds holding: 56 [Q4 2024] → 52 (-4) [Q1 2025]
10% less capital invested
Capital invested by funds: $18.6M [Q4 2024] → $16.6M (-$1.92M) [Q1 2025]
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Research analyst outlook
We haven’t received any recent analyst ratings for ORMP.
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK , April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®.
Neutral
GlobeNewsWire
1 month ago
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the “offering”) whereby an affiliate of Oramed Pharmaceuticals Inc. (“Oramed”) (Nasdaq: ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share.
Neutral
PRNewsWire
3 months ago
Oramed Pharmaceuticals Issues Letter to Shareholders
Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials. Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing.
Neutral
PRNewsWire
4 months ago
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq. OraTech will have global marketing rights to Oramed's POD™ oral protein delivery technology.
Neutral
PRNewsWire
8 months ago
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
NEW YORK , Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the execution of definitive agreements for the restructuring of a portion of its existing Senior Secured Promissory Note from Scilex Holding Company (Nasdaq: SCLX) ("Scilex"), a company focused on non-opioid pain management products. Key Highlights: Oramed, affiliates of Murchinson and 3i LP, entered into definitive agreements with Scilex for the purchase and sale of new tranche B senior secured convertible notes ("Notes") in the aggregate principal amount of $50 million (the "New Financing") and warrants to purchase up to 7,500,000 shares of the Company's common stock in the aggregate in a registered direct offering.
Neutral
InvestorPlace
11 months ago
3 Micro-Cap Moonshots for Fearless Investors
When discussing micro-cap stocks, it's important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million.
Neutral
PRNewsWire
11 months ago
Oramed Letter to Shareholders
Stock Repurchase Program Scilex Senior Secured Note Phase 3 Oral Insulin Trial in US JV with Chinese Partner, HTIT NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed") ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. Dear Shareholders, In light of our recent announcement regarding Oramed's $20 million stock repurchase program, we believe this is an opportune moment to provide our shareholders with a comprehensive update on our activities and progress.
Neutral
PRNewsWire
11 months ago
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months (the "Stock Buy Back Program"). The manner, timing and number of shares purchased will be at the Company's discretion, depending on a number of factors, including price, general business and market conditions, and alternative investment opportunities.
Neutral
PRNewsWire
1 year ago
Oramed Letter to Shareholders
Initiating Phase 3 oral insulin trial in the United States under a new protocol JV with Chinese Partner, HTIT Scilex Senior Secured Note PeriTech Asset Purchase & Strategic Out-licensing NEW YORK , Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron. Dear Shareholders, I am pleased to share with you an update regarding Oramed.
Charts implemented using Lightweight Charts™